Abstracts

881 – Prognostic Factors of Physical Function Decline in the PREPARE Study

Background The Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE) substudy of REPRIEVE found small declines in physical function, and no evidence of pitavastatin effect. However, there was substantial individual variability, with some participants experiencing considerable declines. The purpose of this pre-specified exploratory analysis was to identify participants at a greater risk…

813 – Mitochondrial Haplogroups and Left Ventricular Dysfunction in People Living With and Without HIV

Background Mitochondrial dysfunction is implicated in the development of heart failure, which is more common in people with HIV (PWH) than those without HIV (PWoH). Whether genetic variations in mitochondrial DNA (mtDNA) are related to cardiac dysfunction, specifically left ventricular diastolic dysfunction (LVDD), has not been well studied in PWH. Methods We included men from…

860 – Racial Inequity in Initiation of Semaglutide Therapy Among People With HIV in Care Across the US

Background Antiretroviral therapy has resulted in a reduction in HIV-associated wasting among people with HIV (PWH) and a concomitant rise in overweight and obesity. Semaglutide has been difficult to obtain for some populations, we therefore evaluated use of semaglutide among PWH with medical indications assessing for potential disparities based on race/ethnicity. Methods Our study is…

842 – Multiomics Profiles of SHBG Are Associated With Subclinical Atherosclerosis in Men With HIV

Background Sex hormones and HIV infection both influence cardiovascular health. However, the relationship between sex hormones and subclinical atherosclerosis is not fully understood, especially in the context of HIV. Methods Among 321 men (65% with HIV) from the MACS/WIHS Combined Cohort Study, we measured 14 serum sex hormones and sex hormone-binding globulin (SHBG), assessed carotid…

825 – Dolutegravir-Based Antiretroviral Therapy and Cardiometabolic Health Risk in Persons With HIV

Background Background: Dolutegravir (DTG) based antiretroviral therapy (DTG-ART) is preferred first-line for persons with HIV (PWH), and yet implicated with weight gain. We compared cardiometabolic health risk by DTG-ART.  Methods Methods: ART-experienced PWH enrolled via Makerere University IDI-ART clinic in Uganda (2021), cross-sectional comparisons of DTG-ART and age- and sex-matched controls (group A), and pre-…

811 – Sex Differences in Myocardial Steatosis in South African Youth With Perinatally Acquired HIV

Background Despite studies demonstrating an increase in myocardial steatotic burden in adults with HIV on antiretroviral therapy (ART), no studies have evaluated this phenomenon in youth with perinatally-acquired HIV (YPHIV). Methods The Cape Town Adolescent Antiretroviral Cohort (CTAAC)-Heart study enrolled youth to assess myocardial fibrosis and inflammation using cardiovascular magnetic resonance (CMR). A magnetic resonance…

822 – Social Determinants of Health and the Hypertension Care Cascade in a National HIV Cohort

Background HTN remains a leading modifiable risk factor for cardiovascular, cerebrovascular, and chronic kidney diseases, all disproportionately affecting people with HIV (PWH). Disparities in HTN care have been described in the general population, though such data is limited in PWH. We apply the care cascade framework to HTN to evaluate the association between personal and…

850 – Statin Effect Heterogeneity on Plaque Volume and Composition in the REPRIEVE Mechanistic Substudy

Background REPRIEVE and its Mechanistic Substudy established that pitavastatin prevents major adverse cardiovascular events and reduces noncalcified coronary plaque (NCP) on coronary CT angiography (CTA) among PWH with low-to-moderate traditional ASCVD risk. Here we assess heterogeneity of pitavastatin effects on NCP (density <350 HU) volume and plaque composition, categorized by density (<130HU fibrofatty, 130-350 HU fibrous, >350…

815 – Readmission Risk for Adults With HIV Hospitalized for Heart Failure or Acute Myocardial Infarction

Background People with HIV (PWH) have a higher incidence of cardiovascular disease, including heart failure (HF) and acute myocardial infarction (AMI) than people without HIV (PWoH). In the general population, 30-day readmissions following hospitalizations for HF and AMI are common, and reducing these readmissions is a national quality of care priority. This study compares the 30-day…